Canada based Hepatocellular Carcinoma Clinical Trials & Research Studies Near You (Updated 8/25)

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785

Recruiting

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/04/2025

Locations: Research Site, Phoenix, Arizona +113 locations

Research Site, Phoenix, Arizona

Research Site, Palo Alto, California

Research Site, New Haven, Connecticut

Research Site, Jacksonville, Florida

Research Site, Atlanta, Georgia

Research Site, Grand Rapids, Michigan

Research Site, Rochester, Minnesota

Research Site, New Brunswick, New Jersey

Research Site, Oklahoma City, Oklahoma

Research Site, Arlington, Virginia

Research Site, Milwaukee, Wisconsin

Research Site, Porto Alegre, Not set

Research Site, Santa Maria, Not set

Research Site, Sao Paulo, Not set

Research Site, São Paulo, Not set

Research Site, Vitória, Not set

Research Site, Edmonton, Alberta

Research Site, Halifax, Nova Scotia

Research Site, Barrie, Ontario

Research Site, Cambridge, Ontario

Research Site, Ottawa, Ontario

Research Site, Toronto, Ontario

Research Site, Montréal, Quebec

Research Site, Québec, Quebec

Research Site, Beijing, Not set

Research Site, Changchun, Not set

Research Site, Chengdu, Not set

Research Site, Deyang, Not set

Research Site, Guangzhou, Not set

Research Site, Lishui, Not set

Research Site, Luoyang, Not set

Research Site, Nanchang, Not set

Research Site, Shanghai, Not set

Research Site, Wenzhou, Not set

Research Site, Clichy Cedex, Not set

Research Site, Lille, Not set

Research Site, Lyon Cedex, Not set

Research Site, Nantes Cedex 1, Not set

Research Site, Nice, Not set

Research Site, Pessac Cedex, Not set

Research Site, Rennes, Not set

Research Site, Toulouse, Not set

Research Site, Aachen, Not set

Research Site, Berlin, Not set

Research Site, Bonn, Not set

Research Site, Dortmund, Not set

Research Site, Dresden, Not set

Research Site, Essen, Not set

Research Site, Frankfurt, Not set

Research Site, Göttingen, Not set

Research Site, Hamburg, Not set

Research Site, Hannover, Not set

Research Site, Leipzig, Not set

Research Site, Lübeck, Not set

Research Site, Magdeburg, Not set

Research Site, Moers, Not set

Research Site, München, Not set

Research Site, Regensburg, Not set

Research Site, Ulm, Not set

Research Site, Hong Kong, Not set

Research Site, Shatin, Not set

Research Site, Ahmedabad, Not set

Research Site, Bangalore, Not set

Research Site, Binnaguri, Not set

Research Site, Dehradun, Not set

Research Site, Delhi, Not set

Research Site, Hyderabad, Not set

Research Site, Mumbai, Not set

Research Site, Nashik, Not set

Research Site, Vadodara, Not set

Research Site, Bologna, Not set

Research Site, Milano, Not set

Research Site, Palermo, Not set

Research Site, Perugia, Not set

Research Site, Pisa, Not set

Research Site, Roma, Not set

Research Site, Rozzano, Not set

Research Site, Chiba-shi, Not set

Research Site, Hiroshima-shi, Not set

Research Site, Kashiwa, Not set

Research Site, Kobe-shi, Not set

Research Site, Koto-ku, Not set

Research Site, Kumamoto-shi, Not set

Research Site, Kurume-shi, Not set

Research Site, Kyoto-shi, Not set

Research Site, Morioka-shi, Not set

Research Site, Musashino-shi, Not set

Research Site, Okayama-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Osakasayama-shi, Not set

Research Site, Suita-shi, Not set

Research Site, Tokyo, Not set

Research Site, Yokohama-shi, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Santander, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan, Not set

Research Site, Bangkok, Not set

Research Site, Altındağ, Not set

Research Site, Ankara, Not set

Research Site, Erzurum, Not set

Research Site, Istanbul, Not set

Research Site, Izmir, Not set

Research Site, Hanoi, Not set

Research Site, Ho Chi Minh City, Not set

Research Site, Ho Chi Minh, Not set

Conditions: Hepatocellular Carcinoma

Register for Updates

Learn More ›

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316

Recruiting

In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug. The study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent em... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: az Groeninge - Digestive Oncology, Kortrijk, Not set +9 locations

Conditions: Hepatocellular Carcinoma

Register for Updates

Learn More ›

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

NCT05953337

Recruiting

This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

07/23/2025

Locations: The University of Arizona Cancer Center, Tucson, Arizona +20 locations

Conditions: Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer

Register for Updates

Learn More ›

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

NCT04260802

Recruiting

This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/11/2025

Locations: Cross Cancer Institute, Edmonton, Alberta +4 locations

Conditions: Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer

Register for Updates

Learn More ›

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

NCT03895359

Recruiting

Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients. A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more prec... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/07/2025

Locations: London Health Sciences Centre, London Regional Cancer Program, London, Ontario

Conditions: Hepatocellular Carcinoma

Register for Updates

Learn More ›

Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer

NCT04745390

Recruiting

Radiation is a standard treatment option for patients with liver cancer. Unfortunately, the tumour grows after radiation in many patients and radiation can harm normal tissues. A new treatment using a specialized radiation procedure called Stereotactic body radiotherapy (SBRT) may increase the chance to control liver cancer and reduce the chance of harm to normal tissues. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. S... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/07/2025

Locations: London Regional Cancer Program, London, Ontario

Conditions: Hepatocellular Carcinoma, Liver Metastases

Register for Updates

Learn More ›

A Phase 1, First in Human Study of TORL-4-500 in Patients with Advanced Cancer

NCT06005740

Recruiting

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Mayo Clinic Phoenix, Phoenix, Arizona +9 locations

Conditions: Advanced Solid Tumor, Hepatocellular Carcinoma

Register for Updates

Learn More ›

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

NCT04204850

Recruiting

This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the cancer has come back (recurred). The purpose of this study is to see how useful cabozantinib is in controlling the disease of these patients. Cabozantinib blocks the function of various proteins found on the surface of the body's cells (called receptor tyrosine kinases) t... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/16/2024

Locations: Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Hepatocellular Carcinoma, Recurrent Cancer, Liver Transplant

Register for Updates

Learn More ›

Durvalumab and Tremelimumab in Resectable HCC

NCT05440864

Recruiting

Hepatocellular Carcinoma (HCC) is the third most common cause of death from cancer world wide and the incidence is rising globally. Despite surgical resection in appropriate patients, many patients recur. The results of the IMbrave150 study have established PD-L1 inhibition in combination with VEGF inhibition as a new standard of care highlighting the role of immune checkpoint inhibition in advanced HCC. In addition, the combination of Tremelimumab and Durvalumab has demonstrated efficacy in ad... Read More

Hepatocellular Carcinoma (HCC) is the third most common cause of death from cancer world wide and the incidence is rising globally. Despite surgical resection in appropriate patients, many patients recur. The results of the IMbrave150 study have established PD-L1 inhibition in combination with VEGF inhibition as a new standard of care highlighting the role of immune checkpoint inhibition in advanced HCC. In addition, the combination of Tremelimumab and Durvalumab has demonstrated efficacy in advanced HCC; the HIMALAYA trial has now completed accrual in treatment naïve patients with advanced HCC. Furthermore the earlier use of immune checkpoint inhibitors in this disease are being explored with adjuvant combination strategies, including the EMERALD-2 trial (NCT03847428). Neoadjuvant treatment in HCC allows for delivery of treatment pre surgery and may enhance pathological responses and improve outcomes. The delivery of combination CTLA-4 and PD-L1 inhibition has demonstrated efficacy in other tumour types in the neoadjuvant setting where the impact on the tumour microenvironment has also been evaluated. The safety and feasibility of Durvalumab and Tremelimumab in resectable HCC has yet to be established. Hypotheses Pre-operative (pre-op) Durvalumab and Tremelimumab treatment is safe and feasible in pre surgical setting for upfront resectable HCC The combination of Durvalumab and Tremelimumab pre-op will result in changes in immune and molecular characteristics within the tumour microenvironment. Overall Study Design This is a phase II, open-label multi-centre study to assess safety of Durvalumab and Tremelimumab treatment in pre-op setting for upfront resectable HCC, followed by adjuvant Durvalumab. 28 patients are expected to enrol at three sites. Patients will receive pre-op: 1 dose Tremelimumab (300mg) (T300) with Durvalumab (1500mg) at cycle 1 and 1 further cycle of Durvalumab (1500mg) only. Post-surgical resection, adjuvant therapy will consist of Durvalumab Q4W for up to a maximum of 12 months in total or 13 cycles of Durvalumab (11 cycles post op). All participants will be treated until progressive disease or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met. All participants will be followed for survival until the end of study. No dose reductions of Tremelimumab and Durvalumab will be allowed. Statistics The primary objective of this study is to assess safety of pre-op treatment with Durvalumab and Tremelimumab. For safety, with the null proportion of patients who discontinue treatment due to AEs, imAEs or SAE is 30% versus the alternative proportion is 10% or less than 10%, a sample size of 28 provides 80% power to detect the proportion difference with a two-sided alpha level of 0.1. The sample size estimate is based on the two-sided exact test for binomial proportion considering Binomial Enumeration method. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/07/2024

Locations: University Health Network, Toronto, Ontario +2 locations

Conditions: Hepatocellular Carcinoma

Register for Updates

Learn More ›

Early Detection of Liver Cancer by QUS

NCT06345508

Recruiting

Worldwide, liver cancers are the third most common cause of cancer mortality. Even when liver cancer is suspected by blood tests, imaging is required to determine the location, size, and extent of disease. Medical societies therefore recommend surveillance with ultrasound every 6 months in at-risk patients. However, a key challenge to improving the survival is that ultrasound may miss half of early-stage liver cancers, thus diagnosis must rely on additional tests such as computed tomography (CT)... Read More

Worldwide, liver cancers are the third most common cause of cancer mortality. Even when liver cancer is suspected by blood tests, imaging is required to determine the location, size, and extent of disease. Medical societies therefore recommend surveillance with ultrasound every 6 months in at-risk patients. However, a key challenge to improving the survival is that ultrasound may miss half of early-stage liver cancers, thus diagnosis must rely on additional tests such as computed tomography (CT), magnetic resonance imaging (MRI), or biopsy. Hence, there is a clear need to improve the ability to detect liver cancers, especially with ultrasound. The investigator's team proposes novel ultrasound approaches to detect cancer nodules invisible on conventional ultrasound based on differences in mechanical and structural properties between liver and tumor. Improving detection is critical because liver cancer can be cured only if detected at an early stage, as shown by improvements in survival rates in patients enrolled in surveillance programs. The investigator's multi-disciplinary, national, and international team includes experts in clinical fields (hepatology, oncology, radiology, pathology), basic sciences (engineering, medical physics, machine learning, biostatistics), and patient partnership. The investirgator will apply the methodology of patient partner recruitment and collaborate with the Centre of Excellence on Partnership with Patients and the Public to select potential new collaborators. This will permit this project to be informed at every stage by patient and family perspectives, ensuring that the results of this project will be more robust, impactful, and aligned with the priorities, needs and experiences of those who live with liver cancer. The investigator submits a research proposal focused on advanced imaging techniques because imaging constitutes a foundation for surveillance, diagnosis, staging, treatment selection and assessment of treatment response in patients with liver cancer. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/23/2024

Locations: Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec

Conditions: Hepatocellular Carcinoma, Liver Cancer

Register for Updates

Learn More ›

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

NCT04563338

Recruiting

This study is being done to look at how effective the drug, atezolizumab, with or without the drug bevacizumab, is for people with inoperable liver cancer or non-small lung cancer that has spread to the liver. This will be done by looking at the duration of time from starting the study drug(s) until the cancer worsens in study participants. This study will collect blood and tumor tissue samples from participants to look at changes to their tumor(s) before and after receiving atezolizumab and/or... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/16/2024

Locations: Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases

Register for Updates

Learn More ›

Hepatocellular Carcinoma Clinical Trials in Canada

Match to Clinical Trials